Cargando…

Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes

A retrospective study has shown that EGFr (epidermal growth factor–like repeat) group in the NOTCH3 gene is an important cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) disease modifier of age at first stroke and white matter hyperintensity (WMH)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hack, Remco J., Cerfontaine, Minne N., Gravesteijn, Gido, Tap, Stephan, Hafkemeijer, Anne, van der Grond, Jeroen, Witjes-Ané, Marie-Noëlle, Baas, Frank, Rutten, Julie W., Lesnik Oberstein, Saskia A.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508953/
https://www.ncbi.nlm.nih.gov/pubmed/35862191
http://dx.doi.org/10.1161/STROKEAHA.122.039325
_version_ 1784797129522282496
author Hack, Remco J.
Cerfontaine, Minne N.
Gravesteijn, Gido
Tap, Stephan
Hafkemeijer, Anne
van der Grond, Jeroen
Witjes-Ané, Marie-Noëlle
Baas, Frank
Rutten, Julie W.
Lesnik Oberstein, Saskia A.J.
author_facet Hack, Remco J.
Cerfontaine, Minne N.
Gravesteijn, Gido
Tap, Stephan
Hafkemeijer, Anne
van der Grond, Jeroen
Witjes-Ané, Marie-Noëlle
Baas, Frank
Rutten, Julie W.
Lesnik Oberstein, Saskia A.J.
author_sort Hack, Remco J.
collection PubMed
description A retrospective study has shown that EGFr (epidermal growth factor–like repeat) group in the NOTCH3 gene is an important cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) disease modifier of age at first stroke and white matter hyperintensity (WMH) volume. No study has yet assessed the effect of other known CADASIL modifiers, that is, cardiovascular risk factors and sex, in the context of NOTCH3 EGFr group. In this study, we determined the relative disease-modifying effects of NOTCH3 EGFr group, sex and cardiovascular risk factor on disease severity in the first genotype-driven, large prospective CADASIL cohort study, using a comprehensive battery of CADASIL clinical outcomes and neuroimaging markers. METHODS: Patients with CADASIL participated in a single-center, prospective cohort study (DiViNAS [Disease Variability in NOTCH3 Associated Small Vessel Disease]) between 2017 and 2020. The study protocol included a clinical assessment, neuropsychological test battery and brain magnetic resonance imaging on a single research day. Multivariable linear, logistic and Cox regression models were used to cross-sectionally assess the effect of CADASIL modifiers on clinical severity (stroke, disability, processing speed) and neuroimaging markers (WMH volume, peak width of skeletonized mean diffusivity, lacune volume, brain volume, cerebral microbleed count). RESULTS: Two hundred patients with CADASIL participated, of which 103 harbored a NOTCH3 EGFr 1–6 variant and 97 an EGFr 7–34 variant. NOTCH3 EGFr 1–6 group was the most important modifier of age at first stroke (hazard ratio, 2.45 [95% CI, 1.39–4.31]; P=0.002), lacune volume (odds ratio, 4.31 [95% CI, 2.31–8.04]; P=4.0×10(-6)), WMH volume (B=0.81 [95% CI, 0.60–1.02]; P=1.1×10(-12)), and peak width of skeletonized mean diffusivity (B=0.65 [95% CI, 0.44–0.87]; P=1.6×10(-8)). EGFr 1–6 patients had a significantly higher WMH volume in the anterior temporal lobes and superior frontal gyri and a higher burden of enlarged perivascular spaces. After NOTCH3 EGFr group, male sex and hypertension were the next most important modifiers of clinical outcomes and neuroimaging markers. CONCLUSIONS: NOTCH3 EGFr group is the most important CADASIL disease modifier not only for age at first stroke and WMH volume but also strikingly so for a whole battery of clinically relevant disease measures such as lacune volume and peak width of skeletonized mean diffusivity. NOTCH3 EGFr group is followed in importance by sex, hypertension, diabetes, and smoking.
format Online
Article
Text
id pubmed-9508953
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95089532022-09-26 Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes Hack, Remco J. Cerfontaine, Minne N. Gravesteijn, Gido Tap, Stephan Hafkemeijer, Anne van der Grond, Jeroen Witjes-Ané, Marie-Noëlle Baas, Frank Rutten, Julie W. Lesnik Oberstein, Saskia A.J. Stroke Original Contributions A retrospective study has shown that EGFr (epidermal growth factor–like repeat) group in the NOTCH3 gene is an important cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) disease modifier of age at first stroke and white matter hyperintensity (WMH) volume. No study has yet assessed the effect of other known CADASIL modifiers, that is, cardiovascular risk factors and sex, in the context of NOTCH3 EGFr group. In this study, we determined the relative disease-modifying effects of NOTCH3 EGFr group, sex and cardiovascular risk factor on disease severity in the first genotype-driven, large prospective CADASIL cohort study, using a comprehensive battery of CADASIL clinical outcomes and neuroimaging markers. METHODS: Patients with CADASIL participated in a single-center, prospective cohort study (DiViNAS [Disease Variability in NOTCH3 Associated Small Vessel Disease]) between 2017 and 2020. The study protocol included a clinical assessment, neuropsychological test battery and brain magnetic resonance imaging on a single research day. Multivariable linear, logistic and Cox regression models were used to cross-sectionally assess the effect of CADASIL modifiers on clinical severity (stroke, disability, processing speed) and neuroimaging markers (WMH volume, peak width of skeletonized mean diffusivity, lacune volume, brain volume, cerebral microbleed count). RESULTS: Two hundred patients with CADASIL participated, of which 103 harbored a NOTCH3 EGFr 1–6 variant and 97 an EGFr 7–34 variant. NOTCH3 EGFr 1–6 group was the most important modifier of age at first stroke (hazard ratio, 2.45 [95% CI, 1.39–4.31]; P=0.002), lacune volume (odds ratio, 4.31 [95% CI, 2.31–8.04]; P=4.0×10(-6)), WMH volume (B=0.81 [95% CI, 0.60–1.02]; P=1.1×10(-12)), and peak width of skeletonized mean diffusivity (B=0.65 [95% CI, 0.44–0.87]; P=1.6×10(-8)). EGFr 1–6 patients had a significantly higher WMH volume in the anterior temporal lobes and superior frontal gyri and a higher burden of enlarged perivascular spaces. After NOTCH3 EGFr group, male sex and hypertension were the next most important modifiers of clinical outcomes and neuroimaging markers. CONCLUSIONS: NOTCH3 EGFr group is the most important CADASIL disease modifier not only for age at first stroke and WMH volume but also strikingly so for a whole battery of clinically relevant disease measures such as lacune volume and peak width of skeletonized mean diffusivity. NOTCH3 EGFr group is followed in importance by sex, hypertension, diabetes, and smoking. Lippincott Williams & Wilkins 2022-07-13 2022-10 /pmc/articles/PMC9508953/ /pubmed/35862191 http://dx.doi.org/10.1161/STROKEAHA.122.039325 Text en © 2022 The Authors. https://creativecommons.org/licenses/by/4.0/Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Original Contributions
Hack, Remco J.
Cerfontaine, Minne N.
Gravesteijn, Gido
Tap, Stephan
Hafkemeijer, Anne
van der Grond, Jeroen
Witjes-Ané, Marie-Noëlle
Baas, Frank
Rutten, Julie W.
Lesnik Oberstein, Saskia A.J.
Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes
title Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes
title_full Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes
title_fullStr Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes
title_full_unstemmed Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes
title_short Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes
title_sort effect of notch3 egfr group, sex, and cardiovascular risk factors on cadasil clinical and neuroimaging outcomes
topic Original Contributions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508953/
https://www.ncbi.nlm.nih.gov/pubmed/35862191
http://dx.doi.org/10.1161/STROKEAHA.122.039325
work_keys_str_mv AT hackremcoj effectofnotch3egfrgroupsexandcardiovascularriskfactorsoncadasilclinicalandneuroimagingoutcomes
AT cerfontaineminnen effectofnotch3egfrgroupsexandcardiovascularriskfactorsoncadasilclinicalandneuroimagingoutcomes
AT gravesteijngido effectofnotch3egfrgroupsexandcardiovascularriskfactorsoncadasilclinicalandneuroimagingoutcomes
AT tapstephan effectofnotch3egfrgroupsexandcardiovascularriskfactorsoncadasilclinicalandneuroimagingoutcomes
AT hafkemeijeranne effectofnotch3egfrgroupsexandcardiovascularriskfactorsoncadasilclinicalandneuroimagingoutcomes
AT vandergrondjeroen effectofnotch3egfrgroupsexandcardiovascularriskfactorsoncadasilclinicalandneuroimagingoutcomes
AT witjesanemarienoelle effectofnotch3egfrgroupsexandcardiovascularriskfactorsoncadasilclinicalandneuroimagingoutcomes
AT baasfrank effectofnotch3egfrgroupsexandcardiovascularriskfactorsoncadasilclinicalandneuroimagingoutcomes
AT ruttenjuliew effectofnotch3egfrgroupsexandcardiovascularriskfactorsoncadasilclinicalandneuroimagingoutcomes
AT lesnikobersteinsaskiaaj effectofnotch3egfrgroupsexandcardiovascularriskfactorsoncadasilclinicalandneuroimagingoutcomes